NewBridge Pharmaceuticals

Newbridge Pharmaceuticals, a pharmaceutical, biologics, and medical device company, engages in the sale and marketing of healthcare products. It offers oncology and supportive care products, such as CLASTEON, a bisphosphonate, which treats problems associated with bone metastasis; SANCUSO, a granisetron transdermal system for the prevention of chemotherapy induced nausea and vomiting; and GLICONORM, a film-coated divisible tablet for the treatment of non-insulin dependent diabetes mellitus. The company provides therapeutic products for diseases, such as diabetes, obesity, oncology, and cardiovascular diseases, as well as for other metabolic disorders. It serves biotechnology and pharmaceutical companies in the Middle East, Africa, Turkey, and Caspian Regions. Newbridge Pharmaceuticals was founded in 2007 and is based in Dubai, the United Arab Emirates.

NewBridge Pharmaceuticals headquartered in Asia, operates in the Biotechnology, Pharmaceutical, Medical Device, Oncology sector. The company focuses on Biotechnology and has secured $1.9B in funding across 32 round(s). With a team of 51-100 employees, NewBridge Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - NewBridge Pharmaceuticals, raised $12.0M. Discover more about their projects, partnerships, and impact on our platform.